Title: NHS Consideration of Psilocybin for Depression Treatment Under Scrutiny

Larissa Hope contends that psilocybin, the psychoactive compound found in magic mushrooms, was instrumental in navigating her severe mental health struggles. At age 17, shortly after landing a role in the television series Skins, the sudden spotlight triggered long-suppressed trauma. While conventional antidepressants failed to provide relief, a clinically supervised dose of psilocybin proved to be a pivotal moment. Reflecting on the experience, Hope recalls, "When I experienced it, I burst out crying. It was the first time in my life I had ever felt a sense of belonging and safety in my body. I kept saying, 'I'm home, I'm home'." Nearly two decades later, she attributes her ability to overcome suicidal ideation to this experience, combined with therapeutic support.

However, not all accounts are positive. Jules Evans, a university researcher, recounts a profoundly negative reaction to LSD during his recreational use at age 18. The experience induced a state he describes as "deluded," where he became convinced that everyone was criticizing and judging him. "I thought, I've permanently damaged myself; I've permanently lost my mind," he recalls, labeling it the "most terrifying experience of my life." Evans now directs the Challenging Psychedelic Experiences Project, offering assistance to those suffering adverse effects from psychedelics. He notes that the incident led to lasting social anxiety, panic attacks, and a PTSD diagnosis. These contrasting narratives underscore the complex dilemma currently confronting medical professionals, regulators, and policymakers: Should physicians be permitted to prescribe magic mushrooms and other promising psychedelic substances?

This debate has intensified following recent studies indicating that psychedelic drugs may alleviate symptoms of depression, obsessive-compulsive disorder, PTSD, trauma, and various addictions, including alcohol and gambling dependencies. Currently, the use of psychedelic medicine remains prohibited unless conducted within authorized research frameworks or clinical trials. Since 2022, over 20 trials have evaluated these treatments for conditions such as addiction and PTSD. While numerous studies report beneficial outcomes, several have yielded mixed or inconclusive data, with only a handful finding no significant benefit on primary metrics. The UK’s medicines regulator is currently awaiting results from a major clinical trial led by biotech firm Compass Pathways to help determine whether to ease strict regulations and permit the use of these medicines outside of research settings.

Prof Oliver Howes, chair of the Royal College of Psychiatrists' Psychopharmacology Committee, expresses optimism regarding the potential of these treatments for NHS patients. He highlights the urgent need for more and improved mental health interventions. "These treatments are really interesting because they've shown promise in these small-scale studies… and have the potential to work quicker," he explains. However, he stresses the necessity of rigorous evidence, warning against overstating the benefits before trial results are fully analyzed.

Other experts also advocate for prudence. A report released by the Royal College of Psychiatrists in September 2025 cautioned against the potential risks associated with psychedelics. Medical professionals emphasize that beyond the legal prohibitions, the misuse of these drugs can pose significant health hazards. The history of drug use is as ancient as civilization itself, with substances like magic mushrooms, opium, and cannabis historically utilized for both recreational and ritualistic purposes. By the 1960s and 1970s, LSD, also

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC